Avraham Ashkenazi
@ashkenazilab.bsky.social
Investigating the cell biology of proteostasis and misfolded proteins in neurological disorders. Associate Prof. at Tel Aviv University.
https://en-med.m.tau.ac.il/profile/ashkenaziavi
https://en-med.m.tau.ac.il/profile/ashkenaziavi
Pinned
Targeting UCHL3 attenuates pathological markers in neuronal models of Huntington’s disease
Ishtayeh et al. identify the cancer-associated deubiquitinating enzyme UCHL3 as a potential therapeutic target in Huntington’s disease. Genetic and pharmac
academic.oup.com
Our new paper in @brain1878.bsky.social. 🎉 We identify a new function of #ubiquitin enzyme in #Huntington’s disease models. Great collaboration with the Ellerby Lab.
academic.oup.com/brain/articl...
academic.oup.com/brain/articl...
Reposted by Avraham Ashkenazi
Coffee and improved cognition, reduced dementia
>130,000 people followed 37 years
Benefit seen only with caffeinated coffee or tea and most pronounced ~2 cups/day
@jama.com ☕️☕️https://jamanetwork.com/journals/jama/fullarticle/2844764
>130,000 people followed 37 years
Benefit seen only with caffeinated coffee or tea and most pronounced ~2 cups/day
@jama.com ☕️☕️https://jamanetwork.com/journals/jama/fullarticle/2844764
February 9, 2026 at 4:01 PM
Coffee and improved cognition, reduced dementia
>130,000 people followed 37 years
Benefit seen only with caffeinated coffee or tea and most pronounced ~2 cups/day
@jama.com ☕️☕️https://jamanetwork.com/journals/jama/fullarticle/2844764
>130,000 people followed 37 years
Benefit seen only with caffeinated coffee or tea and most pronounced ~2 cups/day
@jama.com ☕️☕️https://jamanetwork.com/journals/jama/fullarticle/2844764
Whether extracellular vesicles is the primary source for synuclein section is still under investigation. Now it may be use as a biomarker for Parkinson's disease. Super cool.
Clinical Validation of α‐Synuclein in Salivary Extracellular Vesicles as a Biomarker for Parkinson's Disease onlinelibrary.wiley.com/doi/10.1111/...
Clinical Validation of α‐Synuclein in Salivary Extracellular Vesicles as a Biomarker for Parkinson's Disease: A Longitudinal Study
Salivary Extracellular vesicles (SEVs) isolated from PD patients exhibit increased levels of both total (α-SynTot) and oligomeric alpha-synuclein (α-SynOlig). In PD patients, SEVS-α-SynOlig levels co....
onlinelibrary.wiley.com
February 7, 2026 at 12:25 PM
Whether extracellular vesicles is the primary source for synuclein section is still under investigation. Now it may be use as a biomarker for Parkinson's disease. Super cool.
Reposted by Avraham Ashkenazi
Mitochondria as sources and targets of cellular signaling
Mitochondria as sources and targets of cellular signaling
Meichsner et al. review recent insights into mitochondria as dynamic signaling hubs. The authors describe how structural plasticity and interorganellar communication enable mitochondria to serve as both sources and targets of signaling, coordinating stress responses, metabolic adaptation, and innate immune pathways to safeguard cellular homeostasis.
dlvr.it
February 6, 2026 at 11:57 PM
Mitochondria as sources and targets of cellular signaling
Reposted by Avraham Ashkenazi
Parkinson’s disease has the fastest-growing prevalence of any neurodegenerative disorder worldwide
go.nature.com/4r0xZsk
go.nature.com/4r0xZsk
Immune cells from the gut drive development of Parkinson’s disease in the brain
In ‘body-first’ Parkinson’s disease, misfolded proteins propagate from the gut’s nervous system to the brain. Immune-cell activity seems to play a key part in this spread.
go.nature.com
February 6, 2026 at 1:24 PM
Parkinson’s disease has the fastest-growing prevalence of any neurodegenerative disorder worldwide
go.nature.com/4r0xZsk
go.nature.com/4r0xZsk
Reposted by Avraham Ashkenazi
Neurologist Sarah Tabrizi is leading the clinical effort that generate the first gene therapy to treat Huntington’s disease. She’s part of Nature’s 10 for 2025. 🧪
‘Giant step forward’ for Huntington’s — the scientist behind the first gene therapy
Sarah Tabrizi is part of Nature’s 10, a list of people who shaped science in 2025.
go.nature.com
December 31, 2025 at 2:27 PM
Neurologist Sarah Tabrizi is leading the clinical effort that generate the first gene therapy to treat Huntington’s disease. She’s part of Nature’s 10 for 2025. 🧪
Our new paper in @brain1878.bsky.social. 🎉 We identify a new function of #ubiquitin enzyme in #Huntington’s disease models. Great collaboration with the Ellerby Lab.
academic.oup.com/brain/articl...
academic.oup.com/brain/articl...
Targeting UCHL3 attenuates pathological markers in neuronal models of Huntington’s disease
Ishtayeh et al. identify the cancer-associated deubiquitinating enzyme UCHL3 as a potential therapeutic target in Huntington’s disease. Genetic and pharmac
academic.oup.com
February 6, 2026 at 12:13 PM
Our new paper in @brain1878.bsky.social. 🎉 We identify a new function of #ubiquitin enzyme in #Huntington’s disease models. Great collaboration with the Ellerby Lab.
academic.oup.com/brain/articl...
academic.oup.com/brain/articl...